---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-158320"
form_type: "8-K"
ticker: "VOR"
cik: "0001817229"
company_name: "Vor Biopharma Inc."
filed_at: "2024-06-10T23:59:59+00:00"
generated_at: "2026-06-01T05:21:34.791119+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vor Biopharma CFO Nathan Jorgensen resigns; CEO Ang named interim principal financial officer

## Summary
- Nathan Jorgensen resigns as CFO effective June 21, 2024, to pursue a new opportunity; no disagreement cited.
- CEO Robert Ang appointed interim principal financial officer; VP of Finance Amy Quinlan interim principal accounting officer.
- Company has launched search for a permanent CFO.

## SEC filing metadata
- accession: 0001193125-24-158320
- form_type: 8-K
- ticker: VOR
- cik: 0001817229
- company_name: Vor Biopharma Inc.
- filed_at: 2024-06-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817229/000119312524158320/0001193125-24-158320-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817229/000119312524158320/d847248d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-158320
- JSON: https://secwatch.observer/filing/0001193125-24-158320.json
- Plain text: https://secwatch.observer/filing/0001193125-24-158320.txt

## Key facts
- Executive change
  Robert Ang was appointed as Interim Principal Financial Officer at Vor Biopharma Inc..
  - Action: designated
  - Role: Interim Principal Financial Officer
  source text: On June 8, 2024, the Board designated Robert Ang, M.B.B.S., M.B.A., the Company’s President and Chief Executive Officer and a director of the Company, as the Company’s interim principal financial officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817229/000119312524158320/0001193125-24-158320-index.htm
- Executive change
  Amy Quinlan was appointed as Interim Principal Accounting Officer at Vor Biopharma Inc..
  - Action: designated
  - Role: Interim Principal Accounting Officer
  source text: and Amy Quinlan, the Company’s Vice President of Finance, as the Company’s interim principal accounting officer, effective as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817229/000119312524158320/0001193125-24-158320-index.htm
- Executive change
  Nathan Jorgensen resigned as Chief Financial Officer at Vor Biopharma Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On June 4, 2024, Nathan Jorgensen, Ph.D., M.B.A., notified Vor Biopharma Inc. (the “Company”) of his resignation as Chief Financial Officer of the Company, effective as of June 21, 2024 (the “Effective Date”), in order to pursue a new opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817229/000119312524158320/0001193125-24-158320-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.